PT3221313T - Terapia combinada para tratamento de infecções bacterianas resistentes - Google Patents

Terapia combinada para tratamento de infecções bacterianas resistentes

Info

Publication number
PT3221313T
PT3221313T PT15801091T PT15801091T PT3221313T PT 3221313 T PT3221313 T PT 3221313T PT 15801091 T PT15801091 T PT 15801091T PT 15801091 T PT15801091 T PT 15801091T PT 3221313 T PT3221313 T PT 3221313T
Authority
PT
Portugal
Prior art keywords
treatment
combination therapy
bacterial infections
resistant bacterial
resistant
Prior art date
Application number
PT15801091T
Other languages
English (en)
Portuguese (pt)
Inventor
Boudewijn Lodewijk Maria Entasis Therapeutics Limited Dejonge
Thomas Francois Entasis Therapeutics Limited Durand-Reville
Jeroen Cunera Entasis Therapeutics Limited Verheijen
Ruben Entasis Therapeutics Limited Tommasi
John Entasis Therapeutics Limited Mueller
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of PT3221313T publication Critical patent/PT3221313T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15801091T 2014-11-17 2015-11-17 Terapia combinada para tratamento de infecções bacterianas resistentes PT3221313T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17

Publications (1)

Publication Number Publication Date
PT3221313T true PT3221313T (pt) 2019-04-15

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15801091T PT3221313T (pt) 2014-11-17 2015-11-17 Terapia combinada para tratamento de infecções bacterianas resistentes

Country Status (31)

Country Link
US (2) US9968593B2 (enExample)
EP (1) EP3221313B1 (enExample)
JP (1) JP6764862B2 (enExample)
KR (1) KR102542392B1 (enExample)
CN (1) CN107108624B (enExample)
AU (1) AU2015350128B2 (enExample)
BR (1) BR112017010132B1 (enExample)
CA (1) CA2966632C (enExample)
CY (1) CY1121384T1 (enExample)
DK (1) DK3221313T3 (enExample)
EA (1) EA033829B1 (enExample)
ES (1) ES2717776T3 (enExample)
HK (1) HK1244798B (enExample)
HR (1) HRP20190580T1 (enExample)
HU (1) HUE044061T2 (enExample)
IL (1) IL251979B (enExample)
LT (1) LT3221313T (enExample)
ME (1) ME03357B (enExample)
MX (1) MX2017006383A (enExample)
MY (1) MY196240A (enExample)
PH (1) PH12017500852B1 (enExample)
PL (1) PL3221313T3 (enExample)
PT (1) PT3221313T (enExample)
RS (1) RS58429B1 (enExample)
SG (1) SG11201703633TA (enExample)
SI (1) SI3221313T1 (enExample)
SM (1) SMT201900187T1 (enExample)
TR (1) TR201905233T4 (enExample)
TW (1) TWI690317B (enExample)
WO (1) WO2016081452A1 (enExample)
ZA (1) ZA201703245B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044061T2 (hu) 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Kombinációs terápia rezisztens bakteriális fertõzések kezelésére
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
IL289686B2 (en) * 2016-09-16 2023-03-01 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
LT3630111T (lt) 2017-05-08 2022-03-10 Entasis Therapeutics, Inc. Junginiai ir būdai, skirti bakterinių infekcijų gydymui
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
ES2953362T3 (es) * 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
ES3004932T3 (en) * 2020-04-02 2025-03-13 Glaxosmithkline Ip Dev Ltd Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
CN117062598A (zh) * 2021-01-20 2023-11-14 恩塔西斯治疗有限公司 固定剂量抗生素组合物
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046515C (zh) 1993-12-29 1999-11-17 辉瑞大药厂 二氮杂双环神经激肽拮抗剂
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
PT2231667E (pt) * 2008-01-18 2013-12-13 Merck Sharp & Dohme Inibidores de beta-lactamase
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN103687598B (zh) 2011-07-26 2016-03-16 沃克哈特有限公司 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
NZ617104A (en) * 2011-07-26 2015-05-29 Wockhardt Ltd Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
US8822450B2 (en) 2011-08-27 2014-09-02 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
RU2570423C2 (ru) 2011-08-30 2015-12-10 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
CN103781787B (zh) 2011-09-13 2015-09-23 沃克哈特有限公司 含氮化合物及其用途
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
EP2831069B1 (en) 2012-03-30 2017-07-12 Merck Sharp & Dohme Corp. Isoxazole beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
EP2961751B1 (en) 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
EP2934523A1 (en) * 2012-09-03 2015-10-28 Wockhardt Limited Antibacterial compositions
KR20150115761A (ko) * 2013-02-06 2015-10-14 아스트라제네카 아베 병원내 폐렴을 치료하기 위한 조합 요법
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
HUE044061T2 (hu) 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Kombinációs terápia rezisztens bakteriális fertõzések kezelésére

Also Published As

Publication number Publication date
AU2015350128B2 (en) 2019-05-16
IL251979B (en) 2020-10-29
DK3221313T3 (en) 2019-04-08
CN107108624B (zh) 2020-01-07
RS58429B1 (sr) 2019-04-30
HK1244798B (en) 2020-02-21
CA2966632A1 (en) 2016-05-26
TR201905233T4 (tr) 2019-05-21
MX2017006383A (es) 2017-08-21
KR20170082635A (ko) 2017-07-14
MY196240A (en) 2023-03-24
ME03357B (me) 2019-10-20
CA2966632C (en) 2023-10-03
AU2015350128A1 (en) 2017-06-01
SI3221313T1 (sl) 2019-04-30
EP3221313A1 (en) 2017-09-27
PH12017500852A1 (en) 2017-11-06
LT3221313T (lt) 2019-03-25
PH12017500852B1 (en) 2023-03-08
US20180000800A1 (en) 2018-01-04
JP2017533945A (ja) 2017-11-16
ES2717776T3 (es) 2019-06-25
IL251979A0 (en) 2017-06-29
BR112017010132A2 (pt) 2018-01-02
US9968593B2 (en) 2018-05-15
CY1121384T1 (el) 2020-05-29
TW201625234A (zh) 2016-07-16
EA033829B1 (ru) 2019-11-29
WO2016081452A1 (en) 2016-05-26
KR102542392B1 (ko) 2023-06-09
HUE044061T2 (hu) 2019-09-30
EP3221313B1 (en) 2019-01-09
HRP20190580T1 (hr) 2019-05-17
SG11201703633TA (en) 2017-06-29
PL3221313T3 (pl) 2019-07-31
BR112017010132B1 (pt) 2023-02-14
JP6764862B2 (ja) 2020-10-07
US10376499B2 (en) 2019-08-13
NZ731601A (en) 2024-02-23
TWI690317B (zh) 2020-04-11
EA201791069A1 (ru) 2017-11-30
CN107108624A (zh) 2017-08-29
SMT201900187T1 (it) 2019-05-10
US20180289681A1 (en) 2018-10-11
ZA201703245B (en) 2019-08-28

Similar Documents

Publication Publication Date Title
ZA201703245B (en) Combination therapy for treatment of resistant bacterial infections
EP3102225A4 (en) Combination therapy for treatment of hbv infections
PT3212233T (pt) Terapia combinada para o tratamento de doenças
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
GB2547402B (en) Prevention and treatment of microbial infections
SG11201609652RA (en) Treatment of polybacterials infections
IL246453A0 (en) Treatment of non-colic infections using phages
EP3226901A4 (en) Combination therapy for treatment of cancer
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
EP3185884A4 (en) Combination therapy for treatment of cancer
GB201416832D0 (en) Methods of treatment
GB201402909D0 (en) Treating infection
GB201412010D0 (en) Treatment of hypertransaminasemia
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201409434D0 (en) Combinations useful for the treatment of bacterial infectious diseases
GB201619704D0 (en) Treatment of pathogenic infections
GB201501800D0 (en) Treatment of medical conditions
GB201506944D0 (en) Therapeutic treatment
GB201420856D0 (en) Prevention and treatment of microbial infections
AU2014902075A0 (en) New Therapeutic Treatment Combination
AU2014901912A0 (en) Compounds for the treatment of bacterial infections
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer